PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
Recruiting
Phase 4
Interventional Study
Ovarian Stimulation
Quality of Life
Preimplantation Genetic Testing
Fertility Preservation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 40
- Sex
- Female
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 60 (estimated)
- Sponsor
- University Hospital, Ghent · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also co…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Prescreening: Clarification: Pre-screening might be performed to identify women with AFC \> 5 and AMH \> 1.1 ng/ml (Bologna criteria, AFC and AMH values are valid for one year).
Inclusion criteria for:
* Group 1: indication for oocyte cryopreservation
* Group 2: indication for IVF/ICSI and PGT-A
…
Contacts